Latest filing published 16 Mar 2026 for ClearPoint Neuro, Inc..
L. Jeremy Stigall (chief executive) discloses dealings in ClearPoint Neuro, Inc. to SEC (Form 4). We count 29 filings; the first trade dates from 10 June 2022 and the latest from 12 March 2026.
None of the filings is a plain purchase or sale on the open market; they cover grants, option exercises and other movements. Such operations are usually part of compensation schedules, which makes them a weaker signal than an open-market trade.
The latest filing, published on 16 March 2026, reports an option exercise in ClearPoint Neuro, Inc. Typically, a trade is published a median of 2 days after it takes place. Section 16 rules allow two business days to file each Form 4. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
25 of 29 declarations